![Fig. 3. Immunotherapy of A31- or BCL1-bearing mice with BsAb directed against huCD64 on the effector cells and Id on the tumors. / Groups of 5 huCD64+ age-matched mice received 2 μg/d murine G-CSF subcutaneously, 4 days before tumor inoculation, and throughout the course of therapy (10 days in total). Mice were inoculated with either 105 (BCL1) or 2 × 105 (A31) tumor cells intraperitoneally on day 0 and were treated with twice-daily doses of 5 μg BsAb intraperitoneally on days 1 to 5 (50 μg/mouse in total). (This treatment schedule is shown in the inset.) Treatment was as indicated: PBS (●), anti-huCD64 F(ab')2 (⋄), anti-Id F(ab')2 (■), a mixture of anti-Id and anti-huCD64 F(ab')2 (♦), [huCD64 × Id] (○). Symbol labeling on plots shows antibody specificity. Anti-Id Ab preparations were selected for reaction with A31 or BCL1 Id Ig, as appropriate. Survival was recorded daily. Only cohorts treated with [huCD64 × Id] BsAb showed a significant increase in survival over all control groups (P < .02).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/96/10/10.1182_blood.v96.10.3544/5/h82200347003.jpeg?Expires=1735834276&Signature=At1ZhT6jGEDt55HHIwFWuUw26rZORG3eZJydcE4f~7486ZT7smbBToXArU5oNnVeeA8Ch9m3eydyZeB2KDj~Dcd1mKZI5vHjiyR7GjE5AqsPvVeqNyWxi9mCRgwLjJks6avK-iiDP3TsOZLs3fCPRqhwMvobn8Uvl4C4qTbTzyt-eKelTsEK5c-5x-c0KOMTuZW8pIYLSqO56S1IfVr8K6eSioByef0uv36~dl2x7YjEEMPNPHOW12ARZ-LQvgXA-XllFTacw3tXeR8Ihh1KGgoQNUDXwaBVKiXaj9EBhKeeT0CCoL1fKiLqGyGWCnr62q-wnB00z42W5939IW9~ug__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Immunotherapy of A31- or BCL1-bearing mice with BsAb directed against huCD64 on the effector cells and Id on the tumors.
Groups of 5 huCD64+ age-matched mice received 2 μg/d murine G-CSF subcutaneously, 4 days before tumor inoculation, and throughout the course of therapy (10 days in total). Mice were inoculated with either 105 (BCL1) or 2 × 105 (A31) tumor cells intraperitoneally on day 0 and were treated with twice-daily doses of 5 μg BsAb intraperitoneally on days 1 to 5 (50 μg/mouse in total). (This treatment schedule is shown in the inset.) Treatment was as indicated: PBS (●), anti-huCD64 F(ab')2 (⋄), anti-Id F(ab')2 (■), a mixture of anti-Id and anti-huCD64 F(ab')2 (♦), [huCD64 × Id] (○). Symbol labeling on plots shows antibody specificity. Anti-Id Ab preparations were selected for reaction with A31 or BCL1 Id Ig, as appropriate. Survival was recorded daily. Only cohorts treated with [huCD64 × Id] BsAb showed a significant increase in survival over all control groups (P < .02).
